RU99125113A - MANUFACTURE OF ORGANICALLY USED SOLID MEDICINAL FORMS WITH CONTROLLED ALLOCATION OF AN ACTIVE SUBSTANCE - Google Patents
MANUFACTURE OF ORGANICALLY USED SOLID MEDICINAL FORMS WITH CONTROLLED ALLOCATION OF AN ACTIVE SUBSTANCEInfo
- Publication number
- RU99125113A RU99125113A RU99125113/14A RU99125113A RU99125113A RU 99125113 A RU99125113 A RU 99125113A RU 99125113/14 A RU99125113/14 A RU 99125113/14A RU 99125113 A RU99125113 A RU 99125113A RU 99125113 A RU99125113 A RU 99125113A
- Authority
- RU
- Russia
- Prior art keywords
- active substance
- tablets
- content
- solid dosage
- active substances
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims 14
- 238000004519 manufacturing process Methods 0.000 title claims 3
- 239000007787 solid Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 8
- 239000007909 solid dosage form Substances 0.000 claims 4
- 210000004051 Gastric Juice Anatomy 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 238000009792 diffusion process Methods 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 239000002966 varnish Substances 0.000 claims 2
- 230000036826 Excretion Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- -1 hydrogen ions Chemical class 0.000 claims 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims 1
- 238000005453 pelletization Methods 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
Claims (3)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19718012A DE19718012C1 (en) | 1997-04-29 | 1997-04-29 | Process for the production of orally applicable solid pharmaceutical forms with controlled release of active substances |
DE19718012.4 | 1997-04-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99125113A true RU99125113A (en) | 2001-08-20 |
RU2193396C2 RU2193396C2 (en) | 2002-11-27 |
Family
ID=7828056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99125113/14A RU2193396C2 (en) | 1997-04-29 | 1998-04-07 | Method for manufacturing perorally applied solid medicinal forms at controlled release of an active substance |
Country Status (19)
Country | Link |
---|---|
US (1) | US6117450A (en) |
EP (1) | EP0979069B1 (en) |
JP (1) | JP2002511849A (en) |
AR (1) | AR010414A1 (en) |
AT (1) | ATE286723T1 (en) |
AU (1) | AU8009998A (en) |
BR (1) | BR9809328A (en) |
CA (1) | CA2290017C (en) |
CO (1) | CO5070636A1 (en) |
CZ (1) | CZ300174B6 (en) |
DE (2) | DE19718012C1 (en) |
ES (1) | ES2236908T3 (en) |
HU (1) | HU226670B1 (en) |
PL (1) | PL191692B1 (en) |
PT (1) | PT979069E (en) |
RU (1) | RU2193396C2 (en) |
SK (1) | SK147999A3 (en) |
UA (1) | UA49952C2 (en) |
WO (1) | WO1998048782A1 (en) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2775599B1 (en) * | 1998-03-09 | 2001-08-17 | Besins Iscovesco Lab | PHARMACEUTICAL COMPOSITION BASED ON SYNTHESIS NATURAL PROGESTERONE AND OESTRADIOL AND PROCESS FOR PREPARING THE SAME |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US6544553B1 (en) | 1999-12-28 | 2003-04-08 | Watson Pharmaceuticals, Inc. | Dosage forms and methods for oral delivery of progesterone |
US6991807B2 (en) * | 2000-02-24 | 2006-01-31 | Advancis Pharmaceutical, Corp. | Antibiotic composition |
US7025989B2 (en) * | 2000-02-24 | 2006-04-11 | Advancis Pharmaceutical Corp. | Multiple-delayed released antibiotic product, use and formulation thereof |
CA2400784C (en) * | 2000-02-24 | 2009-05-19 | Advanced Pharma, Inc. | Therapeutic product, use and formulation thereof |
AU2001239841B2 (en) * | 2000-02-24 | 2006-04-27 | Shionogi, Inc. | Antibiotic and antifungal compositions |
CA2399856C (en) * | 2000-02-24 | 2009-01-27 | Edward M. Rudnic | Antibiotic composition with inhibitor |
GB0007419D0 (en) † | 2000-03-27 | 2000-05-17 | Smithkline Beecham Gmbh | Composition |
EP1738751B1 (en) * | 2001-01-12 | 2011-05-11 | Sun Pharma Advanced Research Company Ltd | Spaced drug delivery system |
EP1377276B1 (en) * | 2001-04-10 | 2011-10-05 | Sun Pharma Advanced Research Company Limited | Timed pulse release composition |
GB0119848D0 (en) * | 2001-08-15 | 2001-10-10 | Univ Sheffield | Delayed and sustained drug release |
AU2007202779B2 (en) * | 2001-08-15 | 2008-08-07 | University Of Sheffield | Delayed and sustained drug release |
US20030124196A1 (en) * | 2001-08-22 | 2003-07-03 | Susan Weinbach | Pulsatile release compositions and methods for enhanced intestinal drug absorption |
US20030083286A1 (en) * | 2001-08-22 | 2003-05-01 | Ching-Leou Teng | Bioadhesive compositions and methods for enhanced intestinal drug absorption |
JP2005526059A (en) * | 2002-03-07 | 2005-09-02 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic composition |
WO2004108067A2 (en) * | 2003-04-03 | 2004-12-16 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
US8425936B2 (en) * | 2003-07-21 | 2013-04-23 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
JP2006528189A (en) * | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic products, their use and formulation |
AU2004258953B2 (en) * | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
AU2004264356B2 (en) * | 2003-08-12 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
WO2005023184A2 (en) * | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
CA2538064C (en) * | 2003-09-15 | 2013-12-17 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
SE0401031D0 (en) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
EP2468266A3 (en) | 2004-04-22 | 2012-10-24 | AcuCort AB | Pharmaceutical compositions for acute glucocorticoid therapy |
US20080014257A1 (en) * | 2006-07-14 | 2008-01-17 | Par Pharmaceutical, Inc. | Oral dosage forms |
GB0817120D0 (en) * | 2008-09-19 | 2008-10-29 | Diurnal Ltd | Treatment of adrenal insufficiency |
CN102448464A (en) * | 2009-04-07 | 2012-05-09 | 杜奥科特药物公司 | Improved glucocorticoid therapy |
US9375437B2 (en) * | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
US20110312928A1 (en) * | 2010-06-18 | 2011-12-22 | Lipocine Inc. | Progesterone Containing Oral Dosage Forms and Related Methods |
US20110312927A1 (en) * | 2010-06-18 | 2011-12-22 | Satish Kumar Nachaegari | Progesterone Containing Oral Dosage Forms and Related Methods |
CN105412016B (en) * | 2010-10-27 | 2019-01-22 | 上海宣泰医药科技有限公司 | A kind of enteric solid preparation and preparation method thereof containing lycopene, resveratrol or epiphysin |
US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
LT2782584T (en) | 2011-11-23 | 2021-09-10 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
GB201202433D0 (en) | 2012-02-13 | 2012-03-28 | Diurnal Ltd | Controlled drug release |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CA2902911C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US20170035781A1 (en) | 2015-06-22 | 2017-02-09 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2403080A1 (en) * | 1977-09-15 | 1979-04-13 | Heyden Chem Fab | Slow-release nitro:furantoin compsn. useful as urinary antiseptic - comprises three types of granulate with different solubilities |
DE2749749A1 (en) * | 1977-11-07 | 1979-05-10 | Sumitomo Chemical Co | 5-Carboxy-2-acetyl-thiophene prepn. - by oxidising 5-acetyl-2-thienyl-acetic acid with chromic acid or its deriv. |
DE2836355A1 (en) * | 1978-08-19 | 1980-02-28 | Boehringer Sohn Ingelheim | Pharmaceutical preparations in retard form - with active materials in core having semipermeable coating of film former and polymer |
IT1101649B (en) * | 1978-12-15 | 1985-10-07 | Lehner Ag | PROLONGED ACTION PHARMACEUTICAL COMPOSITION CONTAINING BILE ACIDS |
US4728512A (en) * | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
US5229131A (en) * | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
IT1243341B (en) * | 1990-07-13 | 1994-06-10 | Farcon Ag | PHARMACEUTICAL COMPOSITION FOR ORAL USE WITH MODIFIED RELEASE OF NON STEROID ANTI-INFLAMMATORS |
ZA919510B (en) * | 1990-12-05 | 1992-10-28 | Smithkline Beecham Corp | Pharmaceutical compositions |
IT1252198B (en) * | 1991-12-12 | 1995-06-05 | Bayer Italia Spa | PHARMACEUTICAL SYSTEM FOR THERAPEUTICALLY ACTIVE HYDROPYRIDINE CONTROLLED RELEASE ADMINISTRATION AND PREPARATION METHOD |
DE4443175A1 (en) * | 1994-12-05 | 1996-06-13 | Jenapharm Gmbh | New pulsatile drug form |
EP0722732A1 (en) * | 1995-01-24 | 1996-07-24 | Mitsui Toatsu Chemicals, Inc. | Long-acting drug formulation containing pyrimidinedione derivatives |
DE19651551C2 (en) * | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioid antagonist-containing galenic formulation |
WO1998029095A2 (en) * | 1997-01-03 | 1998-07-09 | Elan Corporation, Plc | Sustained release cisapride mini-tablet formulation |
-
1997
- 1997-04-29 DE DE19718012A patent/DE19718012C1/en not_active Expired - Lifetime
-
1998
- 1998-04-07 JP JP54646998A patent/JP2002511849A/en active Pending
- 1998-04-07 AU AU80099/98A patent/AU8009998A/en not_active Abandoned
- 1998-04-07 ES ES98928152T patent/ES2236908T3/en not_active Expired - Lifetime
- 1998-04-07 CA CA002290017A patent/CA2290017C/en not_active Expired - Fee Related
- 1998-04-07 RU RU99125113/14A patent/RU2193396C2/en not_active IP Right Cessation
- 1998-04-07 PL PL336572A patent/PL191692B1/en not_active IP Right Cessation
- 1998-04-07 PT PT98928152T patent/PT979069E/en unknown
- 1998-04-07 HU HU0003121A patent/HU226670B1/en not_active IP Right Cessation
- 1998-04-07 CZ CZ0380499A patent/CZ300174B6/en not_active IP Right Cessation
- 1998-04-07 DE DE59812485T patent/DE59812485D1/en not_active Expired - Lifetime
- 1998-04-07 AT AT98928152T patent/ATE286723T1/en not_active IP Right Cessation
- 1998-04-07 SK SK1479-99A patent/SK147999A3/en unknown
- 1998-04-07 BR BR9809328-2A patent/BR9809328A/en not_active Application Discontinuation
- 1998-04-07 WO PCT/DE1998/000979 patent/WO1998048782A1/en active IP Right Grant
- 1998-04-07 EP EP98928152A patent/EP0979069B1/en not_active Expired - Lifetime
- 1998-04-24 US US09/065,863 patent/US6117450A/en not_active Expired - Fee Related
- 1998-04-29 CO CO98023494A patent/CO5070636A1/en unknown
- 1998-04-29 AR ARP980101982A patent/AR010414A1/en not_active Application Discontinuation
- 1998-07-04 UA UA99116416A patent/UA49952C2/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU99125113A (en) | MANUFACTURE OF ORGANICALLY USED SOLID MEDICINAL FORMS WITH CONTROLLED ALLOCATION OF AN ACTIVE SUBSTANCE | |
RU2193396C2 (en) | Method for manufacturing perorally applied solid medicinal forms at controlled release of an active substance | |
US4842866A (en) | Slow release solid preparation | |
CA1148084A (en) | Dipyridamol sustained release forms and processes for the preparation thereof | |
JP2916978B2 (en) | Controlled release initiation type formulation | |
TW464513B (en) | Controlled release or delayed release formulation containing paroxetine | |
US20070092573A1 (en) | Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist | |
BG97458A (en) | Preparations and methods for the treatment of the alimentary canal | |
CN1226824A (en) | Tramadol multiple unit formulations | |
WO2000010537A1 (en) | Timed release tablet comprising naproxen and pseudoephedrine | |
CN102068414A (en) | Levetiracetam sustained-release tablets and preparation method thereof | |
KR890007743A (en) | Slow Release Galenical Compositions of Pharmaceutically Acceptable Diltiazem | |
Rogers et al. | Reviewing the use of ethylcellulose, methylcellulose and hypromellose in microencapsulation. Part 3: Applications for microcapsules | |
US4656024A (en) | Galenical administration form of METOCLOPRAMIDE, method for its preparation and medicament comprising the new form | |
FR2717388A1 (en) | Sustained release galenic forms of alfuzosin hydrochloride. | |
EP0063266B1 (en) | Galenic preparation | |
RU2205640C1 (en) | Stable mexidol-containing pharmaceutical composition | |
CA1157376A (en) | Pharmaceutical compositions containing paracetamol | |
WO2005016316A1 (en) | Controlled drug release tablets | |
WO1998005306A1 (en) | Controlled release tablet formulation of isosorbide-5-mononitrate | |
Priya et al. | Design and in vitro evaluation of sustained release tablets of ranolazine | |
US3322633A (en) | Pharmaceutical preparations | |
JPH0688901B2 (en) | Liquid long-term release pharmaceutical composition containing ionic drug | |
RU2008015C1 (en) | Process for preparation vitamin formulation "bиtaпektиh" | |
Rao et al. | Design, Evaluation and Comparative Study of Pulsatile Releasefrom Tablet and Capsule Dosage Forms: Pulsatile release from tablet and capsule dosage forms |